HCW Biologics Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z
HCW Biologics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Priorix in Measles; Mumps; Rubella | Measles-Mumps-Rubella Vaccine (Phase 3) using Vaccine.
| Asset | Indication | Modality | Stage | Public Note |
|---|---|---|---|---|
| HCW9206 | use as reagents in the production of immunotherapeutics to treat infectious diseases and cancer | n/a | n/a | Public pipeline row |
| HCW11 | n/a | n/a | Preclinical | Public pipeline row |
| HCW9201 | cancer | n/a | n/a | Public pipeline row |
| HCW9302 | n/a | n/a | Phase 1 | Public pipeline row |
| Priorix | Measles; Mumps; Rubella | Measles-Mumps-Rubella Vaccine | Vaccine | Phase 3 | Public pipeline row |
| V114 | Pneumococcal Infections | Pneumococcal Vaccines | Vaccine | Phase 3 | Public pipeline row |
No public catalyst rows matched this view yet.
Estimated cash runway: Runway < 6 months.
This is an automated estimate and may differ from company guidance.
| NCT ID | Phase | Status | Enrollment | Primary Completion |
|---|---|---|---|---|
| NCT01621802 | Phase 3 | COMPLETED | 4011 | 2015-07-06 |
| NCT02184572 | Phase 3 | COMPLETED | 1742 | 2015-08-14 |
| NCT03893448 | Phase 3 | COMPLETED | 1720 | 2021-05-24 |
Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.
Get the weekly biotech catalyst watchlistThis page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.